Does Urolithin A (Mitopure) boost mitophagy, build muscle strength, and slow aging?
Claim attributed to Amazentis (Mitopure / Timeline); co-founder Johan Auwerx (EPFL) , Amazentis SA sells Urolithin A as Mitopure/Timeline and sponsored every pivotal human trial. Co-founder Johan Auwerx (EPFL) sits on the Scientific Advisory Board; CEO Chris Rinsch and chairman Patrick Aebischer are founders, board members, and shareholders.
The mitophagy mechanism is real in animals and Urolithin A measurably shifts human mitochondrial biomarkers, but the two adequately powered human trials each missed their pre-specified primary endpoint and leaned on secondary measures for the strength headline. "Slows aging" has no human data at all.
It moves your mitochondrial markers in weeks; it has never been shown to make a human stronger on the primary test or to live longer, and the trials that say benefit were paid for by the company selling it.
What it’s supposed to target
- Mitophagy (mitochondrial recycling)
- Mitochondrial quality / biogenesis
- Skeletal-muscle function
- Gut-microbiome conversion
Worn-out mitochondria have to be cleared and replaced through a housekeeping process called mitophagy, which slows with age and leaves cells carrying defective power plants. Urolithin A is not something you eat directly: gut bacteria make it from ellagitannins in pomegranates, berries, and walnuts, and many people's microbiomes barely produce any. The theory is that supplying urolithin A directly switches mitophagy back on, clears the damaged mitochondria, and so restores energy output, especially in muscle.
The mechanism is real in the lab, and human trials confirm urolithin A is safe and does shift mitochondrial gene-expression markers. The functional payoff is where it thins out: trials in older adults show modest and mixed results, with some muscle-endurance and biomarker signals but several primary strength endpoints missed, and most of this work is funded by the company that sells it. No study has tested aging or lifespan. A credible mitochondrial mechanism with early human biomarker support, not the proven anti-aging effect the marketing implies.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
Urolithin A must induce mitophagy and improve mitochondrial health: HOLDS preclinically and at the human biomarker level.
Those molecular shifts must translate into clinically meaningful strength/performance gains in humans: WEAK; both powered RCTs missed their primary functional endpoints.
Such gains must then extend human healthspan or lifespan: UNTESTED; no human aging outcome has ever been measured.
Findings must hold independently of the seller: NOT MET; every pivotal trial was Amazentis-funded with conflicted authors.
What the evidence actually shows
The mechanism is real, but the trials missed their main targets
Urolithin A is a gut metabolite of ellagitannins (pomegranate, walnuts, berries) that induces mitophagy, the clearance of damaged mitochondria. In worms and mice this improves muscle function and extends lifespan/healthspan, and the first human trial (Andreux 2019, *Nature Metabolism*, ~36 elderly) met its safety primary endpoint while shifting muscle mitochondrial gene expression and plasma acylcarnitines, a molecular signature only, with no function tested. But the two adequately powered trials missed their primary functional endpoints: ENERGIZE (Liu 2022) found both co-primary endpoints (6-minute walk, maximal ATP production) not significant, and ATLAS (Singh 2022) missed its primary peak-power endpoint.
The strength headline is a secondary endpoint; aging is untested
ATLAS's widely cited ~12% improvement was a *secondary* outcome (hamstring/knee-flexion torque, p~.03), while hand-grip and quadriceps strength were not significant, and 6-minute walk, VO2, and gait-speed changes at 1000 mg were within-group only and not significant versus placebo (6MWT p=.098; VO2 p=.058). ENERGIZE's endurance signal was significant at 2 months but attenuated by 4 months. An independent ADDF/Cognitive Vitality review confirms lifespan benefit is "potential benefit in animal models" only and that both trials missed their primary endpoints. No human trial has measured aging, mortality, or disease incidence.
Studies, graded, and who paid
Well supported in worms/mice for mechanism; human trials confirm bioavailability and lower acylcarnitines, ceramides, CRP, and shift muscle gene expression.
ENERGIZE and ATLAS both missed primary functional endpoints; positive strength signals are secondary, inconsistent, dose-dependent, and not independently replicated.
No human lifespan, mortality, or disease-incidence data; rests on animal models plus surrogate biomarkers.
Well tolerated at 500-1000 mg/day over 4 weeks to 4 months; long-term safety untested.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 36 | Andreux 2019, Nature Metabolism (first-in-human) | RCT, double-blind, placebo-controlled safety/PK; single dose + 4 weeks, ~n=36 | ~36 healthy sedentary elderly | Industry-funded Funded by Amazentis SA; authors include Amazentis founders/employees (Rinsch, Auwerx, Aebischer, Singh). | Primary endpoint was safety; no strength or function tested; 4 weeks; small. |
| 66 | Liu 2022, ENERGIZE, JAMA Network Open | RCT, double-blind, placebo-controlled; 1000 mg/day, 4 months | 66 older adults (33 UA / 33 placebo; mean ~72) | Industry-funded "This research was supported by Amazentis SA." D'Amico, Singh employees; Rinsch founder/CEO/board; Aebischer chair/shareholder. | Both co-primary endpoints (6-min walk, max ATP) missed; endurance secondary, attenuated by 4 months; ~76% female, 100% White. |
| 88 | Singh 2022, ATLAS, Cell Reports Medicine | RCT, double-blind, placebo-controlled, 3-arm; 500/1000 mg, 4 months | 88 untrained overweight middle-aged (29/29/30) | Industry-funded "This study was funded by Amazentis SA." Multiple authors employees/board; Auwerx and Aebischer on Scientific Advisory Board of the sponsor. | Primary peak-power endpoint missed; 12% gain is secondary torque; grip/quadriceps NS; 6MWT/VO2/gait within-group, NS vs placebo. |
| 0 | ADDF / Cognitive Vitality evidence review (Oct 2024) | Independent evidence review (no primary participants) | Review | Independent ADDF/Cognitive Vitality is a non-industry reviewer. | Narrative review; confirms animal-only lifespan data and both missed primary endpoints; "good safety but limited benefits in short term studies so far." |
Surrogate biomarker shifts (acylcarnitines, ceramides, CRP, mitochondrial gene expression) are not validated proxies for strength or longevity; a marker moving is not an outcome changing.
Unproven ≠ disproven
The 'slows aging' claim is unproven, not disproven: no human lifespan or disease-incidence trial has been run, and such a trial would take years to a decade.
Where claim and evidence diverge
The gap is between molecular signatures (real, measurable) and clinical outcomes (strength inconsistent, aging never tested), and between sponsor-run trials and absent independent replication.
The money trail
Amazentis sells Mitopure and funded all three pivotal trials; authors include its employees, founders, board members, and shareholders, and co-founder Auwerx sits on its Scientific Advisory Board. This is a fact to weigh: favourable secondary-endpoint headlines from sponsor-run trials warrant a downgrade until an independent group replicates them.
The honest read
Urolithin A reliably triggers mitophagy in animals and nudges human mitochondrial biomarkers with a clean short-term safety record, but the human strength benefit is modest, secondary, and unreplicated, and 'slows aging' is unmeasured in people. Plausible and biomarker-active, not proven to build strength or extend life.
What would change this verdict
A large, independent (non-Amazentis) RCT that hits a pre-specified primary strength or performance endpoint versus placebo.
A long-term human trial showing reduced disease incidence, disability, or mortality, rather than only biomarker shifts.
Sources
- Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1:595-603.
- Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults (ENERGIZE): A Randomized Clinical Trial. JAMA Network Open. 2022;5(1):e2144279.
- Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults (ATLAS). Cell Reports Medicine. 2022;3(5):100633.
- Cognitive Vitality / Alzheimer's Drug Discovery Foundation (ADDF). Urolithin A supplement evidence review (updated Oct 2024).
People also ask
- Does Urolithin A actually improve muscle strength?
- The evidence is mixed. The two adequately powered human trials, ENERGIZE and ATLAS, both missed their pre-specified primary functional endpoints. The positive strength signals are secondary, inconsistent, dose-dependent, and not independently replicated, so the strength headline rests on weaker measures.
- Does Urolithin A really boost mitophagy in humans?
- The mitophagy mechanism is well supported in worms and mice. In humans, Urolithin A confirms bioavailability and measurably shifts mitochondrial biomarkers, lowering acylcarnitines, ceramides and CRP and shifting muscle gene expression. The molecular signature is real and measurable.
- Can Urolithin A slow aging?
- There is no human data showing it slows aging. The claim rests on animal models plus surrogate biomarkers, with no human lifespan, mortality, or disease-incidence evidence. Plausible and biomarker-active is not the same as proven to extend life.
- Is Mitopure safe to take?
- Short-term safety looks good. Urolithin A was well tolerated at 500 to 1000 mg per day over four weeks to four months. Long-term safety, however, has not been tested, so durability beyond a few months is unknown.
Part of our guide: Longevity supplements, fact-checked
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.